Tecnologías de la información y la comunicación como herramienta educativa en pacientes con enfermedades crónicas no transmisibles en una IPS de la ciudad de Manizales

ABSTRACT Introduction: chronic noncommunicable  diseases cause high morbidity and mortality worldwide so it requires innovative strategies that impact on self-care, adoption of healthy lifestyles and the diseases treatment. Nowadays, the information and communication technologies compose a resource in order to improve the effectiveness and efficiency of the patient’s programs with chronic diseases, overcome structural limitations and the availability of human resources in the health system. Objective: to evaluate the impact of theinformation and communication technologies to promote healthy lifestyles and adherence to medication, to know the perception of users about the usefulness of the intervention and also their effect on clinical variables. Methods: longitudinal study, in which 90 patients outpatient health institution in Manizales were included to receive text messages, was made. There were chosen over-age-18 men and women, with arterial hypertension diagnosis or diabetes mellitus who owned a cell phone or were with a near carer assistant who would accept receiving text massages in its own mobile. The massages were about their healthy lifestyle, and these were sent between august and december during 29 weeks. 68 subject completed the follow up. At the end of the intervention, acceptance, usefulness and effects on laboratory and clinical parameters were evaluated. Results: it was found that 100% of the patients who confirmed receiving the messages perceived an improvement in self care; showing changes in diet (95.16%) and the amelioration of medication adherence (59%). Besides, the service utility was qualified as excellent. Conclusions: the patient’s perceptions about the use of the information and communication technologies was positive and it could generates changes in areas such as alimentary habits and medication adherence, in promoting healthy lifestyles and management of chronic noncommunicable diseases. However, it requires controlled studies using a standardized long-term monitoring to determine the actual impact on clinical variables and cost-effective. In addition, it should identify the type of population would get greater benefit. MÉD.UIS. 2016;29(2):59-70.Keywords: Diabetes Mellitus. Hypertension. Primary prevention. Text Messaging. Cell Phones. Education. Technology.Introducción: las enfermedades crónicas no transmisibles causan gran morbilidad y mortalidad a nivel mundial por lo que se requiere de estrategias innovadoras que impacten en el autocuidado, adopción de estilos de vida saludables y manejo de ellas. En la actualidad, las Tecnologías de la información y la comunicación constituyen un recurso para mejorar la efectividad y la eicacia de programas dirigidos a pacientes con enfermedades crónicas, superar las limitaciones estructurales y la disponibilidad de recursos humanos existentes en los sistemas de salud. Objetivo: evaluar el impacto de las Tecnologías de la información y la comunicación como herramienta educativa para promover estilos de vida saludables y adherencia a la medicación, conocer la percepción de los usuarios frente a la intervención y observar el efecto sobre variables clínicas. Materiales y Métodos: estudio longitudinal, donde se incluyeron 90 pacientes de la consulta externa de una institución prestadora de salud de Manizales para recibir mensajes de texto. Fueron seleccionados hombres y mujeres mayores de 18 años con diagnóstico de hipertensión arterial o diabetes mellitus con teléfono celular propio o de un cuidador cercano que aceptaran recibir los mensajes de texto en su teléfono móvil. Los mensajes contenían información sobre estilos de vida saludable y fueron enviados entre agosto y diciembre de 2014 durante 29 semanas. 68 sujetos completaron el seguimiento. Al inal de la intervención, se evaluó la aceptación, utilidad y efectos sobre parámetros de laboratorio y clínicos. Resultados: el 100% de los pacientes que conirmaron la recepción de los mensajes percibieron una mejoría en su autocuidado; evidenciándose cambios en la dieta (95,16%) y mejoría en la adherencia a la medicación (59%), además de caliicarse la utilidad del servicio como excelente por el 61,5% de los sujetos. Sin embargo no se encontraron cambios estadísticamente signiicativos en variables clínicas y de laboratorio. Conclusiones: la percepción de los pacientes frente al uso de las Tecnologías de la información y la comunicación es positiva y genera cambios en aspectos como la alimentación y la adherencia a la medicación, por lo que constituye una herramienta en la promoción de estilos de vida saludables y manejo de enfermedades crónicas no transmisibles. Se requiere de estudios controlados estandarizados mediante un seguimiento a largo plazo para determinar el impacto real sobre variables clínicas y su costo-beneicio. Además se deberá individualizar el tipo de población que obtendría mayor beneicio. MÉD. UIS. 2016;29(2):59-70.Palabras clave: Diabetes Mellitus. Hipertensión. Prevención primaria. Mensaje de texto. Teléfonos celulares. Educación. Tecnología.

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). Methods: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care. Results: Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67-0.95]; P=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49-0.94]) and secondary (HR, 0.85 [95% CI, 0.69-1.06]) prevention groups (P for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61-1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59-1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56-1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction >0.5 for each outcome). Conclusions: Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure &lt; 100 mmHg (n = 1127), estimated glomerular filtration rate &lt; 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

Síndrome metabólico en la mujer

Resumen: Introducción: La obesidad, especialmente la abdominal, se asocia con la resistencia al efecto de la insulina sobre la glucosa periférica y la utilización de ácidos grasos, hecho que puede conducir al desarrollo de síndrome metabólico y a la diabetes mellitus tipo 2. La resistencia a la insulina, la hiperinsulinemia y la hiperglucemia asociada, y el aumento de adipoquinas también puede llevar a la disfunción endotelial vascular, perfil anormal de lípidos, hipertensión e inflamación vascular, todo lo cual promueve el desarrollo de enfermedad cardiovascular aterosclerótica; a esa asociación se le conoce como síndrome x, cuarteto de la muerte, síndrome de resistencia a la insulina.En el estudio NHANES III, el síndrome metabólico estaba presente en el 5% de los pacientes de peso normal, 22% de los que tenían sobrepeso, y el 60% de aquellos que eran obesos. El aumento del peso corporal es un factor de riesgo importante para el síndrome metabólico, además de la edad y la raza, otros factores asociados con un mayor riesgo de síndrome metabólico, el consumo de bebidas endulzadas con azúcar y medicamentos antipsicóticos. Objetivo: Determinar cómo influye el síndrome metabólico en la mujer en el aumento de riesgo cardiovascular. Método: Se realizó una revisión sistemática de las investigaciones y de las revisiones de tema que se han realizado en últimos años sobre el síndrome metabólico en la mujer, a partir de los hallazgos arrojados de bases de datos científicas. Uptodate, PubMed y SciELO. Conclusiones: La enfermedad cardiovascular es la principal causa de muerte en las mujeres y existen factores de riesgo específicos de la mujer para desarrollarla, entre los cuales están: edad temprana de menarquia, menopausia, síndrome premenstrual, síndrome de ovario poliquístico, uso de anticonceptivos orales, haber presentado trastorno hipertensivo del embarazo, parto pretérmino y otros factores de riesgo compartidos con los hombres, como edad, antecedentes familiares, hipertensión arterial, dislipidemias, diabetes mellitus, síndrome metabólico, enfermedad renal crónica, tabaquismo, dieta, consumo de alcohol, sedentarismo, obesidad, factores psicosociales, marcadores inflamatorios, proteína C reactiva, concentración elevada de fibrinógeno plasmático e hiperhomocisteinemia. Abstract: Introduction: Obesity, especially abdominal obesity, is associated with resistance to the effect of insulin on peripheral glucose and the use of fatty acids. This can lead to the development of metabolic syndrome and type 2 diabetes mellitus, resistance to insulin, hyperinsulinemia and associated hyperglycemia, and adipokines. It can also lead to vascular endothelial dysfunction, an abnormal lipid profile, hypertension and vascular inflammation, all of which promote the development of atherosclerotic cardiovascular disease. This association is known as syndrome X, the quartet of death, or insulin resistance syndrome.In the NHANES III study, metabolic syndrome was present in 5% of patients with normal weight, 22% of those who were overweight, and 60% of those who were obese. Increased body weight is a major risk factor for metabolic syndrome, in addition to age and race. Other factors associated with an increased risk of metabolic syndrome include the consumption of drinks sweetened with sugar and antipsychotic medications.In this review, we will discuss how metabolic syndrome affects women in increasing cardiovascular risk. Method: A systematic review of the research was carried out, with the subject reviews which have been carried out in recent years regarding metabolic syndrome in women, derived from scientific data bases. Uptodate, Pubmed and Scielo. Conclusions: Cardiovascular disease (CVD) is the main cause of death in women and there are risk factors which are specific to women, such as early onset of menarche, menopause, premenstrual syndrome, polycystic ovarian syndrome, the use of oral contraceptives, a history of pregnancy induced hypertension, and preterm delivery. Other risk factors are shared with men, such as age, family history, hypertension, dyslipidemias, diabetes mellitus, metabolic syndrome, chronic kidney disease, smoking, diet, consumption of alcohol, a sedentary lifestyle, obesity, psychosocial factors, C-reactive protein inflammatory markers, a high plasma fibrinogen level and hyperhomocysteinemia. Palabras clave: Síndrome metabólico, Mujer, Factores de riesgo, Keywords: Metabolic syndrome, Women, Risk factor

Tecnologías de la información y la comunicación como herramienta educativa en pacientes con enfermedades crónicas no transmisibles en una IPS de la ciudad de Manizales

Introducción: las enfermedades crónicas no transmisibles causan gran morbilidad y mortalidad a nivel mundial por lo que se requiere de estrategias innovadoras que impacten en el autocuidado, adopción de estilos de vida saludables y manejo de ellas. En la actualidad, las Tecnologías de la información y la comunicación constituyen un recurso para mejorar la efectividad y la eicacia de programas dirigidos a pacientes con enfermedades crónicas, superar las limitaciones estructurales y la disponibilidad de recursos humanos existentes en los sistemas de salud. Objetivo: evaluar el impacto de las Tecnologías de la información y la comunicación como herramienta educativa para promover estilos de vida saludables y adherencia a la medicación, conocer la percepción de los usuarios frente a la intervención y observar el efecto sobre variables clínicas. Materiales y Métodos: estudio longitudinal, donde se incluyeron 90 pacientes de la consulta externa de una institución prestadora de salud de Manizales para recibir mensajes de texto. Fueron seleccionados hombres y mujeres mayores de 18 años con diagnóstico de hipertensión arterial o diabetes mellitus con teléfono celular propio o de un cuidador cercano que aceptaran recibir los mensajes de texto en su teléfono móvil. Los mensajes contenían información sobre estilos de vida saludable y fueron enviados entre agosto y diciembre de 2014 durante 29 semanas. 68 sujetos completaron el seguimiento. Al inal de la intervención, se evaluó la aceptación, utilidad y efectos sobre parámetros de laboratorio y clínicos. Resultados: el 100% de los pacientes que conirmaron la recepción de los mensajes percibieron una mejoría en su autocuidado; evidenciándose cambios en la dieta (95,16%) y mejoría en la adherencia a la medicación (59%), además de caliicarse la utilidad del servicio como excelente por el 61,5% de los sujetos. Sin embargo no se encontraron cambios estadísticamente signiicativos en variables clínicas y de laboratorio. Conclusiones: la percepción de los pacientes frente al uso de las Tecnologías de la información y la comunicación es positiva y genera cambios en aspectos como la alimentación y la adherencia a la medicación, por lo que constituye una herramienta en la promoción de estilos de vida saludables y manejo de enfermedades crónicas no transmisibles. Se requiere de estudios controlados estandarizados mediante un seguimiento a largo plazo para determinar el impacto real sobre variables clínicas y su costo-beneicio. Además se deberá individualizar el tipo de población que obtendría mayor beneicio

Medición,control y conocimiento de la presión arterial: Iniciativa Mayo Mes de la Medición Colombia 2017

La prevalencia de presión arterial es alta en esta población adulta joven,en la cual el desconocimiento de la condición de HTA estambién alta,y en aquellos que conocen su condición existe un porcentaje bajo de control de la HTA, resultados que de muestran la necesi-dad de implementar programas eficaces de detección de pacientes hipertensos y de establecer tratamientos estandarizados para mejorar el control de la HTA como una estrategia para la reducción de eventos cardiovasculares.The prevalence of blood pressure is high in this young adult population, in which ignorance of the HTA condition is also high, and in those who know their condition there is a low percentage of control of the HTA, results that show the need To implement effective programs for the detection of hypertensive patients and to establish standardized treatments to improve the control of HT as a strategy for the reduction of cardiovascular events.Introducción. -- Materiales y métodos. -- Resultados y Discusión000066948220131202747https://orcid.org/0000-0002-2328-7468https://scienti.minciencias.gov.co/gruplac/jsp/visualiza/[email protected]